^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    m-ceNK cells

    i
    Other names: m-ceNK cells, memory cytokine-enriched natural killer cells
    Associations

    News

    Trials
    Company:
    ImmunityBio
    Drug class:
    NK cell stimulant, IFNγ stimulant
    Related drugs:
    Associations

    News

    Trials
    11ms
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, ImmunityBio, Inc. | N=30 --> 50 | Trial completion date: Jun 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    almost3years
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, ImmunityBio, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells
    almost3years
    QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, ImmunityBio, Inc.
    Clinical • New P1 trial
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells